Cisplatin versus carboplatin: comparative review of therapeutic management in solid malignancies

被引：253

作者：

Ho, Gwo Yaw ^{[1
,2
,4
]}

Woodward, Natasha ^{[2
]}

Coward, Jermaine I. G. ^{[1
,2
,3
]}

机构：

[1] Univ Queensland, Sch Med, Brisbane, Qld 4072, Australia

[2] Mater Hlth Serv, Raymond Terrace, South Brisbane, Qld 4101, Australia

[3] Princess Alexandra Hosp, Ipswich Rd, Woolloongabba, Qld 4102, Australia

[4] Walter & Eliza Hall Inst Med Res, 1G Royal Parade, Parkville, Vic 3052, Australia

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2016年 / 102卷

关键词：

Cisplatin; Carboplatin; Radio-sensitisation; Platinum-based chemotherapy; Platinum resistance; Platinum sensitivity; PHASE-III TRIAL; UNKNOWN PRIMARY SITE; RECURRENT ENDOMETRIAL CARCINOMA; PEMETREXED PLUS CARBOPLATIN; TRANSITIONAL-CELL CARCINOMA; NUCLEOTIDE EXCISION-REPAIR; MESSENGER-RNA EXPRESSION; LOCALLY ADVANCED HEAD; RANDOMIZED-TRIAL; OVARIAN-CANCER;

D O I：

10.1016/j.critrevonc.2016.03.014

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The platinum analogues, cisplatin and carboplatin, are among the most widely used chemotherapeutic agents in oncology. Both agents have a broad spectrum of clinical activity in numerous malignancies including gynaecological cancers, germ cell tumours, head and neck cancer, thoracic cancers and bladder cancer. Although the final mechanism of inducing tumour cell apoptosis is similar for both compounds, cisplatin has been shown to be more effective in treating specific tumour types. Whilst more favourable toxicity profiles are often associated with carboplatin, this can frequently translate to inferior response in certain malignancies. This review succinctly collates the evidence for the preferential use of these platinum analogues in particular settings in addition to the long-standing dilemma surrounding the paucity of biomarkers predicting response to these agents. (C) 2016 Elsevier Ireland Ltd. All rights reserved.

引用

页码：37 / 46

页数：10

共 98 条

[31] Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer "Unfit" for Cisplatin-Based Chemotherapy: Phase II-Results of EORTC Study 30986 [J].

De Santis, Maria ;

Bellmunt, Joaquim ;

Mead, Graham ;

Kerst, J. Martijn ;

Leahy, Michael ;

Maroto, Pablo ;

Skoneczna, Iwona ;

Marreaud, Sandrine ;

de Wit, Ronald ;

Sylvester, Richard .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (33) :5634-5639

[32] Favorable outcome of ovarian germ cell malignancies treated with cisplatin or carboplatin-based chemotherapy: A Hellenic Cooperative Oncology Group study [J].

Dimopoulos, MA ;

Papadopoulou, M ;

Andreopoulou, E ;

Papadimitriou, C ;

Pavlidis, N ;

Aravantinos, G ;

Aspropotamitis, A ;

Anagnostopoulos, A ;

Fountzilas, G ;

Michalas, S ;

Pectacides, D .

GYNECOLOGIC ONCOLOGY, 1998, 70 (01) :70-74

[33] Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium:: Results of a randomized phase 2 trial [J].

Dogliotti, Luigi ;

Carteni, Giacomo ;

Siena, Salvatore ;

Bertetto, Oscar ;

Martoni, Andrea ;

Bono, Aldo ;

Amadori, Dino ;

Onat, Haluk ;

Marini, Luca .

EUROPEAN UROLOGY, 2007, 52 (01) :134-141

[34] A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer [J].

du Bois, A ;

Lück, HJ ;

Meier, W ;

Adams, HP ;

Möbus, V ;

Costa, S ;

Bauknecht, T ;

Richter, B ;

Warm, M ;

Schröder, W ;

Olbricht, S ;

Nitz, U ;

Jackisch, C ;

Emons, G ;

Wagner, U ;

Kuhn, W ;

Pfisterer, J .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (17) :1320-1330

[35] A phase I study of carboplatin concurrent with radiation in figo stage IIIB cervix uteri carcinoma [J].

Duenas-Gonzalez, A ;

Cetina, L ;

Sánchez, B ;

Gomez, E ;

Rivera, L ;

Hinojosa, J ;

López-Graniel, C ;

Gonzalez-Enciso, A ;

de la Garza, J .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2003, 56 (05) :1361-1365

[36] A phase II study of carboplatin and paclitaxel in esophageal cancer [J].

El-Rayes, BF ;

Shields, A ;

Zalupski, M ;

Heilbrun, LK ;

Jain, V ;

Terry, D ;

Ferris, A ;

Philip, PA .

ANNALS OF ONCOLOGY, 2004, 15 (06) :960-965

[37] A phase II study of carboplatin and paclitaxel in adenocarcinoma of unknown primary [J].

El-Rayes, BF ;

Shields, AF ;

Zalupski, M ;

Heilbrun, LK ;

Jain, V ;

Terry, D ;

Ferris, AM ;

Philip, PA .

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2005, 28 (02) :152-156

[38] RANDOMIZED COMPARISON OF CISPLATIN PLUS FLUOROURACIL AND CARBOPLATIN PLUS FLUOROURACIL VERSUS METHOTREXATE IN ADVANCED SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK - A SOUTHWEST-ONCOLOGY-GROUP STUDY [J].

FORASTIERE, AA ;

METCH, B ;

SCHULLER, DE ;

ENSLEY, JF ;

HUTCHINS, LF ;

TRIOZZI, P ;

KISH, JA ;

MCCLURE, S ;

VONFELDT, E ;

WILLIAMSON, SK ;

VONHOFF, DD .

JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (08) :1245-1251

[39] Carcinoma of unknown primary site: Phase II trials with docetaxel plus cisplatin or carboplatin [J].

Greco, FA ;

Erland, JB ;

Morrissey, LH ;

Burris III, HA ;

Hermann, RC ;

Steis, R ;

Thompson, D ;

Gray, J ;

Hainsworth, JD .

ANNALS OF ONCOLOGY, 2000, 11 (02) :211-215

[40] Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis [J].

Green, JA ;

Kirwan, JM ;

Tierney, JF ;

Symonds, P ;

Fresco, L ;

Collingwood, M ;

Williams, CJ .

LANCET, 2001, 358 (9284) :781-786

← 1 2 3 4 5 6 7 8 9 10 →